In 2010, the therapeutic cancer vaccine market witnessed several key
milestones. Dendreon' s Provenge (sipuleucel-T) became the first product to
reach the market; gaining long-awaited FDA approval for metastatic
hormone-refractory prostate cancer. The Cancer Research Institute (CRI) and
the Cancer Immunotherapy Consortium (CIC) also proposed much needed criteria
to standardize vaccine clinical trials.
Although the major milestones attained in the clinical development of
therapeutic cancer vaccines has brought hope and guidance for investors, the
market is in its commercial infancy. According to Arrowhead' s new publication:
The Global Cancer Vaccine Market, 2nd Edition: Pipeline Analysis and Future
Market Impact, numerous challenges must be overcome to create optimal
vaccines on an economical scale. Stakeholders can learn from Provenge' s
developmental pathway to maximize success in this potentially lucrative market.
With over 1.3 million people having been diagnosed with colorectal cancer,
breast cancer, lung cancer, prostate cancer, pancreatic cancer or melanoma
across the seven major markets in 2010, coupled with unsatisfactory survival
rates; vaccines could hold the ability to transform the management of cancer.
This in-depth report provides:
An identification and analysis of the major challenges within therapeutic
cancer vaccine R&D including clinical trial standardization recommendations ,
designing optimal vaccines and the lessons learnt from Provenge' s development
pathway
Clinical and commercial analysis of key Phase III oncology vaccine
candidates
An overview and analysis of the current markets for the treatment of
various cancers
Insight from key opinion leaders (KOLs) on the future applicability of
therapeutic vaccines for the treatment of cancer
Sales growth rates to 2020 for key products in development
Report highlights
Traditional cancer clinical trial endpoints are not always applicable in the
assessment of cancer vaccines. Lengthy trials allowing full data maturation of
measuring immune response is limiting market entry. R&D must establish an
effective and consistent way to assess vaccines.
Arrowhead has identified almost 400 clinical trials investigating therapeutic
oncology vaccines. Whole-cell vaccines are the most popular design in
late-stage development. Arrowhead anticipates a wave of products to reach the
market over the coming decade.
The market is set to become highly competitive, especially within the lung
cancer and melanoma sectors. By 2020 the market could be worth $8 billion. Top
revenue earning candidates include GSK' s MAGE-ASCI-A3, Merck/Oncothyreon' s
Stimuvax (BLP25), NovaRX' s Lucanix and Lorus Therapeutics/Zor Pharma' s
Virulizin.
Key questions answered by this report
How can therapeutic cancer vaccine clinical trials be optimized to aid
regulatory approval and commercial success?
What lessons can stakeholders learn from Provenge' s developmental and
commercial pathway?
What is the optimal design of a therapeutic cancer vaccine?
What candidates are in the current therapeutic cancer vaccine pipeline?
What are the key pipeline therapeutic cancer vaccine candidates in
late-stage development?
What are the clinical and commercial attributes of key late-stage
therapeutic cancer vaccine candidates?
Which biopharmaceutical companies are involved in the arena?
What revenues will therapeutic cancer vaccine products generate over the
next coming decade?
Which cancer types will realize the greatest benefits from vaccines?
What major challenges face the arena over the coming years; and how can
these be overcome?
What advice do leading expert immunology/oncology vaccine developers give
to stakeholders in the arena?
What are the greatest commercial opportunities within the future
therapeutic cancer vaccine market?
Reasons to buy this report
Identify key therapeutic cancer vaccine candidates in late-phase
development based on sales forecasts to 2020 to maximize your products
commercial potential
Assess opportunities and risks influencing R&D in therapeutic cancer
vaccines
Gain an impartial perspective of strategies that can be used to enhance
new product performance in the therapeutic cancer vaccine market
Better understand how cancer vaccines will fit into future therapeutic
regimens for cancer
Table of Contents
Table of Contents
1 EXECUTIVE SUMMARY
1.1 Scope of Global Cancer Vaccine Market, 2nd Edition: the Potential
Revolution of Oncology Management
1.2 Methodology of Global Cancer Vaccine Market, 2nd Edition: the
Potential Revolution of Oncology Management
1.3 Epidemiology of Cancer in the Seven Major Markets
1.4 Key Challenges in Therapeutic Cancer Vaccine R&D
1.5 Therapeutic Cancer Vaccines Pipeline Analysis
1.6 Therapeutic Cancer Vaccines Market Analysis
2 THE EPIDEMIOLOGICAL AND ECONOMIC IMPACT OF CANCER
2.1 Cancer Across the Globe
2.2 Cancer in the US
2.3 Cancer Survival Rates
2.4 The Economic Impact of Cancer
3 INTRODUCTION TO THERAPEUTIC CANCER VACCINES
3.1 The Immune System and Cancer
3.2 What are Vaccines?
3.3 Unmet Needs in Current Cancer Therapy
3.4 The Basics of Cancer Vaccines
3.5 Why Therapeutic Cancer Vaccines?
3.6 Early Efforts of Cancer Vaccines
3.7 Allogeneic Versus Autologous Vaccines
3.8 Types of Cancer Vaccines
3.8.1 Viral Vectors and DNA Vaccines
3.8.2 Antigen/Adjuvant Vaccines
3.8.3 Whole-Cell Cancer Vaccines
3.8.4 Anti-Idiotype Vaccines
3.8.5 Dendritic Cell Vaccines
4 VACCINES AND THE COLORECTAL CANCER THERAPEUTIC MARKET
4.1 Overview of Colorectal Cancer
4.1.1 Prognosis of Colorectal Cancer
4.2 Epidemiology of Colorectal Cancer in the Seven Major Markets
4.3 The Therapeutic Management of Colorectal Cancer
4.3.1 An Overview of Chemotherapy for Colorectal Cancer
4.3.2 Amgen' s Vectibix (panitumumab)
4.3.3 Roche' s Avastin (bevacizumab)
4.3.4 Clinical Analysis of Arrowhead' s Leading Brand Product in the
Colorectal Cancer Market: ImClone/Bristol-Myers Squibb/Merck KgaA' s Erbitux
(cetuximab)
4.4 Revenue Review of Colorectal Cancer Branded Products
4.5 Unmet Needs in the Colorectal Cancer Market
4.6 Therapeutic Colorectal Cancer Vaccine Pipeline Analysis
4.6.1 Vaccinogen' s Oncovax (oncovax-o)
4.7 Colorectal Cancer Market Commentary
4.7.1 Financial Forecast of Therapeutic Colorectal Cancer Vaccines
5 VACCINES AND THE PROSTATE CANCER THERAPEUTIC MARKET
5.1 Overview of Prostate Cancer
5.1.1 Prognosis of Prostate Cancer
5.2 Epidemiology of Prostate Cancer in the Seven Major Markets
5.3 The Therapeutic Management of Prostate Cancer
5.3.1 An Overview of Chemotherapy for Prostate Cancer
5.3.2 Sanofi-Aventis' Taxotere (docetaxol)
5.3.3 Clinical Analysis of Arrowhead' s Leading Brand Product in the
Prostate Cancer Market: Dendreon' s Provenege (spiuleucel-t)
5.4 Revenue Review of Prostate Cancer Branded Products
5.5 Unmet Needs in the Prostate Cancer Market
5.6 Therapeutic Prostate Cancer Vaccine Pipeline Analysis
5.6.1 Bavarian Nordic/NCI' s Prostvac
5.6.2 Northwest Biotherapeutic' s DCVax (dcax- prostate)
5.7 Prostate Cancer Therapeutics Market Commentary
5.7.1 Financial Forecast of Therapeutic Prostate Cancer Vaccines
6 VACCINES AND THE LUNG CANCER THERAPEUTIC MARKET
6.1 Lung Cancer Overview
6.1.1 Prognosis of Lung Cancer
6.2 Epidemiology of Lung Cancer in the Seven Major Markets
6.3 The Therapeutic Management of Lung Cancer
6.3.1 An Overview of Chemotherapy for Lung Cancer
6.3.2 Roche' s Avastin (bevacizumab)
6.3.3 AstraZeneca' s Iressa (gefitinib)
6.3.4 Clinical Analysis of Arrowhead' s Leading Brand in the Lung
Cancer Market: Roche' s Tarceva (erlotinib)
6.4 Revenue Review of Lung Cancer Branded Products
6.5 Unmet Needs in the Lung Cancer Market
6.6 Therapeutic Lung Cancer Vaccines Pipeline Analysis
6.6.1 Nova Rx' s Lucanix
6.6.2 Transgene/Novartis' TG4010 (mva-muc-il2)
6.6.3 GlaxoSmithKline' s MAGE-A3-ASCI (GSK1572932A)
6.6.4 Merck/Oncothyreon' s Stimuvax (BLP25)
6.7 LUNG CANCER THERAPEUTICS MARKET COMMENTARY
6.7.1 Financial Forecast of Therapeutic Lung Cancer Vaccines
7 VACCINES AND THE BREAST CANCER MARKET
7.1 Breast Cancer Overview
7.1.1 Prognosis of Breast Cancer
7.2 Epidemiology of Breast Cancer in the Seven Major Markets
7.3 The Therapeutic Management of Breast Cancer
7.3.1 An Overview of Chemotherapy for Breast Cancer
7.3.2 GlaxoSmithKline' s Tykerb/Tyverb (lapatinib)
7.3.3 Clinical Analysis of Arrowhead' s Leading Brand in the Breast
Cancer Market: Roche' s Herceptin (trastuzumab)
7.4 Revenue Review of Breast Cancer Branded Products
7.5 Unmet Needs in the Breast Cancer Market
7.6 Therapeutic Breast Cancer Vaccine Pipeline Analysis
7.6.1 Celldex' s CDX1307
7.7 Breast Cancer Therapeutics Market Commentary
7.7.1 Financial Forecast of Breast Cancer Therapeutic Vaccines
8 VACCINES AND THE PANCREATIC CANCER MARKET
8.1 Pancreatic Cancer Overview
8.1.1 Prognosis of Pancreatic Cancer
8.2 Epidemiology of Pancreatic Cancer in the Seven Major Markets
8.3 The Therapeutic Management of Pancreatic Cancer
8.3.1 An Overview of Chemotherapy for Pancreatic Cancer
8.3.2 Roche' s Tarceva (erlotinib)
8.3.3 Clinical Analysis of Arrowhead' s Leading Brand Product in the
Pancreatic Cancer Market: Eli-Lilly' s Gemzar (gemcitabine)
8.4 Revenue Review of Pancreatic Cancer Branded Products
8.5 Unmet Needs in the Pancreatic Cancer Market
8.6 Therapeutic Pancreatic Cancer Vaccine Pipeline Analysis
8.6.1 Kael/GemVax' s GV1001
8.6.2 Lorus Therapeutic/Zor Pharma' s Virulizin
8.7 Pancreatic Cancer Therapeutic Market Commentary
8.7.1 Financial Forecast of Pancreatic Cancer Therapeutic Vaccines
9 VACCINES AND THE MELANOMA MARKET
9.1 Melanoma Overview
9.1.1 Prognosis of Melanoma
9.2 Epidemiology of Melanoma in the Seven Major Markets
9.3 The Therapeutic Management of Melanoma
9.3.1 An Overview of Chemotherapy for Melanoma
9.3.2 Merck/Schering-Plough' s Intron-A (interferon-Alfa 2b)
9.3.3 Clinical Analysis of Arrowhead' s Leading Brand in the Melanoma
Market: Novartis' Proleukin (aldesleukin)
Table 50: FDA' s Considerations for Therapeutic Cancer Vaccine Clinical
Trials
Table 51: Challenges and Recommendations for Assessment of Cancer
Immunotherapies
Table 52: The Relative Advantages of Different Therapeutic Cancer Vaccine
Designs
Table 53: Current Late Stage and Phase II Therapeutic Cancer Vaccines
Pipeline, November 2010
Table 54: Development Status Updates of Selected Phase III Therapeutic
Cancer Vaccines
Table 55: Therapeutic Cancer Vaccines Revenue Forecast 2010-2020 ($
millions)
LIST OF FIGURES
Figure 1: Colorectal, Prostate, Lung, Breast, Pancreatic and Melanoma
Cancer Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 2: Cancer Incidence Forecast in the Seven Major Markets, 2010 and
2020
Figure 3: Key Challenges in Therapeutic Cancer Vaccine R&D
Figure 4: The Late-Stage Therapeutic Cancer Vaccine Pipeline by the
Number of Candidates of Different Vaccine Type Design, November 2010
Figure 5: Comparison of the Value of the Therapeutic Cancer Vaccine
Market, 2010 and 2020
Figure 6: Cancer Incidence Worldwide by Geographic Region, 2008
Figure 7: Worldwide Number of Cancer Cases for Males and Females
Combined, 2008
Figure 8: Schematic Diagram of the Production of DNA/Viral Vector Vaccines
Figure 9: Schematic Diagram of Antigen/Adjuvant Vaccines Mode of Action
Figure 10: Schematic Diagram of Whole-Cell Tumor Vaccine Production
Figure 11: Schematic Diagram of Anti-Idiotype Vaccine Production
Figure 12: Schematic Diagram of Dendritic Cell Cancer Vaccine Production
Figure 13: The Anatomy of the Human Digestive System
Figure 14: Colorectal Cancer Incidence Forecast in the Seven Major
Markets, 2008-2020
Figure 15: OncoVax' s Treatment Schedule
Figure 16: The Anatomy of the Male Reproductive System
Figure 17: Prostate Cancer Incidence Forecast in the Seven Major Markets,
2008-2020
Figure 18: The Anatomy of the Human Respiratory System
Figure 19: Lung Cancer Incidence Forecast in the Seven Major Markets,
2008-2020
Figure 20: The Anatomy of the Human Breast
Figure 21: Breast Cancer Incidence Forecast in the Seven Major Markets,
2008-2020
Figure 22: The Anatomy of the Human Pancreas
Figure 23: Pancreatic Cancer Incidence Forecast in the Seven Major
Markets, 2008-2020
Figure 24: The Anatomy of Human Skin
Figure 25: Melanoma Incidence Forecast in the Seven Major Markets,
2008-2020
Figure 26: The Current Therapeutic Cancer Vaccine Pipeline by the Number
of Candidates by Vaccine Type, November 2010
Figure 27: SWOT Analysis of the Therapeutic Cancer Vaccine Market, 2010
Figure 28: Therapeutic Cancer Vaccines Revenue Forecast 2010-2020 ($
millions)
Figure 29: Total Therapeutic Cancer Vaccine Market Revenue Forecast
2010-2020 ($ millions)
The Global Cancer Vaccine Market, 2nd Edition: Pipeline Analysis and Future Market Impact published by Arrowhead Publishers in January 5, 2011. This report price starts from US $ 2750.
